InvestorsHub Logo
Followers 1320
Posts 26909
Boards Moderated 6
Alias Born 12/10/2012

Re: None

Thursday, 04/09/2020 12:02:52 PM

Thursday, April 09, 2020 12:02:52 PM

Post# of 111
$WCOTF: Wow.... supplying into MBRX for Covid-19


WPD Pharma Research Shows WP1122 Could Reduce Replication of Covid-19 Virus
8:50 AM ET 4/9/20 | Dow Jones
Related Quotes


12:01 PM ET 4/9/20
Symbol Last % Chg
CNSP
3.70 34.49%
MBRX
1.18 -7.48%
Real time quote.



By Chris Wack

WPD Pharmaceuticals Inc. said Thursday that independent research on its WP1122 drug compound found 2-deoxy-D-glucose to reduce replication of SARS-CoV-2, the virus that causes Covid-19, by 100% in in vitro testing.

WPD said it would collaborate with its development partner CNS Pharmaceuticals Inc. to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2.

WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech Inc.

"We are excited with this breakthrough on our WP1122 drug candidate and the early implications are that it could have positive effects on reducing the spread of Covid-19," commented Mariusz Olejniczak, chief executive of WPD.

CNS Pharma shares were up 18%, to $3.25, in premarket trading. Moleculin Biotech shares were up 5%, to $1.34.

Write to Chris Wack at chris.wack@wsj.com

> Dow Jones Newswires

April 09, 2020 08:50 ET (12:50 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.


GO $WCOTF